Takeda Pharmaceutical (TAK) Short-term Investments (2017 - 2026)

Takeda Pharmaceutical's Short-term Investments history runs 10 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 99.01% year-over-year to $267.1 million in Q1 2026; TTM through Mar 2026 was $267.1 million, a 99.01% increase from a year earlier, with the FY2026 full-year figure at $278.3 million, up 107.01% from the prior year.
• Short-term Investments declined to $267.1 million in Q1 2026 per TAK's latest filing, from $2.8 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $2.8 billion in Q4 2025 and bottomed at $101.8 million in Q1 2024.
• The 5-year median for Short-term Investments is $2.1 billion (2023), against an average of $1.6 billion.
• Across the five-year window, Short-term Investments tumbled 37.02% in 2022 and soared 99.01% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $1.9 billion in 2022, then decreased by 6.31% to $1.8 billion in 2023, then surged by 43.36% to $2.6 billion in 2024, then grew by 5.36% to $2.8 billion in 2025, then plunged by 90.3% to $267.1 million in 2026.
• Per Business Quant, the three latest TAK Short-term Investments figures stand at $267.1 million (Q1 2026), $2.8 billion (Q4 2025), and $2.5 billion (Q3 2025).